Mesoblast Limited (MESO) Stock Price & How to Invest

Mesoblast Limited is a Melbourne-based biopharmaceutical company founded in 2004 by Dr. Silviu Itescu, who still runs it, and it develops allogeneic (off the shelf) mesenchymal stromal cell medicines for severe inflammatory disease. Its lead product, Ryoncil (remestemcel-L-rknd), was approved by the FDA in December 2024 for steroid-refractory acute graft versus host disease in children two months and older, making it the first FDA-approved mesenchymal stromal cell therapy. The regimen is eight intravenous infusions over four weeks at a list price of about $194,000 per infusion, which puts a full course near $1.55 million before rebates, chargebacks and patient assistance. A commercial team of roughly ten representatives sells into about 45 priority transplant centers that handle around 80 percent of U.S. pediatric transplants, and coverage now reaches more than 250 million insured U.S. lives including fee-for-service Medicaid. Mesoblast also earns royalties on TEMCELL, the same cell technology marketed in Japan by licensee JCR Pharmaceuticals, and holds more than 1,000 granted patents and applications running to at least 2044.

The investment picture rests on one launched product and several unapproved ones. Ryoncil net revenue climbed from about $11.3 million in the stub quarter after the late-March 2025 launch to roughly $30.3 million in the March 2026 quarter and about $36 million in the June 2026 quarter, for a preliminary full-year fiscal 2026 total near $115 million. Gross margin is high, with cost of sales of about $7.6 million against roughly $48.7 million of product sales in the December 2025 half, but research and development of about $46.2 million and selling and administrative costs of about $28.5 million in that same half keep the company loss-making. At roughly $15.60 per ADS the market value is close to $2.1 billion, or about 17 times fiscal 2026 revenue, which prices in adult graft versus host disease, chronic low back pain and other indications that have not yet been approved. Ordinary shares outstanding roughly doubled between mid-2022 and mid-2025, so dilution has been a persistent feature of how this company funds itself.

Nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once. The adult GvHD, chronic low back pain, LVAD-related bleeding and Duchenne muscular dystrophy programs are all unapproved, and Mesoblast has a long history of FDA setbacks, including the 2020 complete response letter that preceded a four-year delay to approval. Ordinary shares roughly doubled from about 650 million in mid-2022 to about 1.28 billion in mid-2025, and the company has said it will need additional capital beyond the next twelve months, so further dilution is a reasonable expectation. Book equity of about $575 million at December 31, 2025 is almost entirely intangible assets and goodwill at roughly $569 million, which means the price-to-book ratio understates how little tangible net asset backing there is. Prior management guidance and pipeline timelines have slipped repeatedly, and the fiscal 2026 revenue figures are preliminary and subject to completion of the audit.

We give no verdict on Mesoblast Limited. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Ryoncil's first full year of sales. Ryoncil generated roughly $115 million of net revenue in the fiscal year ended June 30, 2026, its first complete year on the market, with about $66.5 million of that in the second half.

The case against. Nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once.

Read the full bull and bear case on MESO, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Mesoblast Limited's investor relations page or your broker.

• Market cap: ~$2.1B (ADS ~$15.60, ~132M ADS outstanding)
• Ryoncil net revenue (FY2026, year to June 30, 2026): ~$115M, preliminary and unaudited
• Revenue (H1 FY2026, six months to Dec 31, 2025): ~$51.3M, of which ~$48.7M product sales
• Net loss (H1 FY2026): ~$40.2M
• Net operating cash spend (FY2026): ~$43.8M
• Cash: ~$103M at June 30, 2026

Mesoblast reports in U.S. dollars under IFRS even though the parent company's functional currency is the Australian dollar, and its fiscal year ends June 30, so figures quoted as fiscal 2026 cover July 2025 through June 2026. Screeners that show a trailing twelve-month revenue near $65 million are running on the period through December 31, 2025 and understate the current run rate, which puts the multiple closer to 17 times sales than 30 times. The audited fiscal 2026 annual report on Form 20-F had not been filed as of mid-August 2026, so the full-year figures above come from the July 2026 quarterly activity statement.

Other names that sit close to MESO: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MESO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MESO sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MESO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Mesoblast now has a marketed product and a repaired balance sheet, and the open question is whether label expansion and the rexlemestrocel-L pipeline can grow into a market value near $2.1 billion.

Whether MESO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MESO a buy or a sell?, and where the stock could go from here in the MESO stock forecast.

For income investors, whether MESO pays a dividend and how the payout looks is covered in does MESO pay a dividend? And to weigh MESO against a peer, read the full side-by-side comparisons: MESO vs INCY and MESO vs SNY.